The balance between pro- and anti-apoptotic BCL-2 family proteins is critical in determining cell fate decisions, and manipulating this balance to breach the apoptotic threshold is an attractive strategy in cancer therapeutics [70]. This evidence concerns the gene BCL2 and cancer.